The vaccine story will not change the demands for gloves worldwide for many, many more months to come. All industry need to use glove for hygiene purposes. This is a new norm.
KUALA LUMPUR (Nov 10): After posting a strong set of results for the third quarter ended Sept 30, 2020 (3QFY20), analysts expect Kossan Rubber Industries Bhd to record even stronger earnings for the next quarter (4QFY20), in tandem with rising average selling prices (ASPs) of gloves.
Net profit for the glove maker’s 3QFY20 surged 609% to RM348.74 million from RM49.18 million for the previous corresponding quarter, thanks to higher sales volume and selling prices as demand for rubber gloves continued to outstrip supply amid the Covid-19 pandemic.
Quarterly revenue jumped 95% to RM1.03 billion from RM531.26 million for 3QFY19. For the cumulative nine-month period ended Sept 30, 2020 (9MFY20), Kossan's net profit more than tripled to RM544.6 million from RM163.78 million for the year-ago period, while cumulative revenue grew 43% to RM2.35 billion from RM1.64 billion previously.
RHB Research Institute maintained its "buy" call for the stock with a higher target price (TP) of RM9, noting that the group’s expansion plans remain intact, with its capacity already up by 10% to 32 billion pieces per year, with a further addition of 1.5 billion pieces with the construction of Plant 20, which is due to be fully commissioned by the first half of 2021 (1H21).
The research house added that Kossan also stands a chance to join the FBM KLCI next month if it maintains its current market capitalisation of around RM17.6 billion.
“We increase our FY20-22 earnings [forecasts] by 91%-160% to reflect higher ASPs, in line with the industry trend. The higher TP is in line with better earnings estimates. In the near term, we expect Kossan to register a stronger set of results for 4QFY20, in line with the industry’s higher ASP trend. In the long run, Kossan is a beneficiary of a long-term global uptrend in glove consumption,” said RHB analyst Alan Lim.
Despite a strong set of results, the stock had fallen 8.27% or 62 sen to RM6.88 as at the time of writing today, in tandem with other glove counters which topped the loser list on Bursa Malaysia this morning as news of Pfizer’s Covid-19 vaccine candidate dominated the market’s optimism about ending the global pandemic and reopening the economy. Still, year to date, the stock has enjoyed a bull run with a 227% leap.
On another note, the fresh development of the potential vaccine could hamper Kossan’s share price in the near term, noted PublicInvest Research.
“Nonetheless, we think that it would still take about two years to have the entire global population vaccinated upon the roll-out of a vaccine, therefore any short-term price weakness would be an opportunity for investors to accumulate,” it said in a note today, upgrading its call for the stock to "trading buy" with a higher TP of RM9.40.
AmInvestment Bank, on the other hand, maintained its "hold" call for the stock with a lower fair value (FV) of RM7.07.
“We like Kossan as it is one of the biggest glove producers to benefit from the Covid-19 pandemic due to its expansionary plans and efforts in improving quality and operational efficiency. However, we believe that the stock is fully valued with a price-earnings ratio (PER) of 29 times [forecasted] FY22 earnings per share (EPS),” said AmInvestment Bank analyst Thong Pak Leng.
Thong noted that Kossan’s capacity had been fully taken up until end-2021, while still receiving orders for 2022.
“Around 10%-15% of its total capacity has been allocated for spot orders. Management indicated that incoming capacity will be directed to short-term orders,” he said.
TLDR: Don't panic if you hear about vaccine. Glove demand will always be high
Careplus Group Berhad - Press Statement UPDATE ON COVID-19 SITUATION
We regret to inform that there are workers in our factory tested positive for Covid-19 and they are now under the care of a government hospital.
We had immediately taken the necessary actions which include closure of the affected factory facilities to facilitate thorough disinfection and sanitisation in accordance to the guidelines of the Ministry of Health (“MOH”).
An uncompleted vaccine & reaction is like tomorrow we can start our normal life again. Eg. Go genting gamble/fly with airasia/unemployment rate back to normal/shopping/etc. Come on la! I'm happy with the news as well, but it takes time. Baru 90% success rate. Need to be perfected and save to use for everyone.
*The same Pfizer trial was halted one month ago. No report published on it yet. So much of discrepancies unsettled. Chill bro, chill...
Pfizer stock gone up by mere 7.7%. But bursa oil and gas counters gone up by 15%. This shows how unreasonable the market is. Tomorrow many counters will pull back where they belong.
usually, gap down with bullish inverted hammer is a sign of reversal..will we see a reversal on the price back to where it previously belong? lets wait tomorrow
@gemfinder pfizer what? pfizer 2 days in a row red candle even though gap up..its just a matter of time before it went down again..just show how unsure traders with the vaccine eventhough the hope is there
Careplus Group Bhd said some workers in its factory at the Senawang Industrial Estate in Negeri Sembilan have tested positive for Covid-19. They are now under the care of a government hospital. We had immediately taken necessary actions which include closure of the affected factory facilities, to facilitate thorough disinfection and sanitisation in accordance with the guidelines of the Ministry of Health (MoH).
Careplus executive director and group CEO Lim Kwee Shyan said the group has arranged for all of its 2,000 staff to undergo Covid-19 testing. He declined to disclose how many workers have tested positive, saying the information will be released by the relevant authorities. Lim said the operations at all its factories have been halted for two days, as they are all located at the same place. As a result, the group’s production capacities will be affected during this period, he said, adding he expects production to resume gradually over the next two weeks.
Meanwhile, Careplus will continue with its glove shipments based on the availability of stocks in the warehouse. Careplus said it is working closely with MoH to perform contact tracing and is also making the necessary arrangements for employees in close contact with the affected workers, to undergo the swab test. They will be placed on home quarantine, pending their Covid-19 test results. The group said it has also immediately activated work from home arrangements for all non-critical employees. We will continue to work closely with MoH and will adhere to the guidelines and standard operating procedures to ensure the safety and wellbeing of our employees.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
x20x20
30 posts
Posted by x20x20 > 2020-11-10 14:53 | Report Abuse
The vaccine story will not change the demands for gloves worldwide for many, many more months to come. All industry need to use glove for hygiene purposes. This is a new norm.